logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
V

Vilde Drageset Haakensen

Oslo University Hospital
H指数:28
被引数:2,407

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy

非小细胞肺癌患者化疗放疗期间肠道微生物群的改变

Molecular Oncology
IF4.5
2026-09-140
OA
Hanne Marte Nymoen; Zhi Zhao; Henrik Horndalsveen; Maria Moksnes Bjaanæs; Bjørn Henning Grønberg; Tarje Halvorsen; Tesfaye Madebo; Marianne Aanerud; Jussi Koivunen; Kersti Oselin; Saulius Cicenas; Nina Helbekkmo; Jarkko Ahvonen; Maria Silvoniemi; Tine Norman Alver; Tonje Dalen; Åsa Kristina Öjlert; Saima Jamil Farooqi; Åslaug Helland; Vilde Drageset Haakensen
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy

《PACIFIC-R》真实世界研究中，不可切除III期非小细胞肺癌患者接受化疗放疗后使用durvalumab治疗的患者放射性肺炎的发生模式及相关因素。

Clinical and Translational Radiation Oncology
IF2.7
2026-02-230
OAAI
Andrea R. Filippi; Jair Bar; Daniel C. Christoph; John K. Field; Rainer Fietkau; Marina Chiara Garassino; Pilar Garrido; Vilde Drageset Haakensen; Steven Kao; Fiona McDonald; Francoise Mornex; Mor Moskovitz; Solange Peters; Michel M. Van Den Heuvel; Piet Vercauter; Hans J.M. Smit; Benjamin Solomon; Pratibha Chander; Yao Qiao; Jolyon Faria
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab

血液基肿瘤突变负荷作为接受化疗联合放疗及durvalumab治疗不可切除非小细胞肺癌的生物标志物

Frontiers in Oncology
IF3.3
2025-10-220
OAAI
Henrik Horndalsveen; Vilde Drageset Haakensen; Tesfaye Madebo; Bjørn Henning Grønberg; Tarje Onsøien Halvorsen; Jussi Koivunen; Kersti Oselin; Saulius Cicenas; Nina Helbekkmo; Marianne Aanerud; Jarkko Ahvonen; Maria Silvoniemi; Maria Moksnes Bjaanæs; Saima Farooqi; Daniel Nebdal; Astrid Marie Dalsgaard; Britina Kjuul Danielsen; Mari Børve; Tonje Sofie Dalen; Åsa Kristina Öjlert; Åslaug Helland
Radiotherapy (RT) patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients (pts) with Stage III unresectable non-small cell lung cancer (UR-NSCLC) treated with durvalumab (D) after chemoradiotherapy (CRT)

放射治疗（RT）模式及与PACIFIC-R研究中肺炎相关的因素，该研究是一项真实世界研究，研究对象为接受化疗放疗（CRT）后使用度伐利尤单抗（D）治疗的III期不可切除非小细胞肺癌（UR-NSCLC）患者（pts）。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Filippi, A. R.; Bar, J.; Christoph, D. C.; Field, J. K.; Fietkau, R.; Garassino, M. C.; Garrido Lopez, P.; Haakensen, V. D.; Kao, S. C-H.; McDonald, F.; Mornex, F.; Moskovitz, M.; Peters, S.; van den Heuvel, M.; Vercauter, P.; Smit, H. J. M.; Chander, P.; Qiao, Y.; Faria, J.; Girard, N.
Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma

NIPU试验的更新生存数据和疫苗反应：一项评估纳武利尤单抗和伊匹木单抗联合或不联合UV1疫苗接种在胸膜间皮瘤患者中的随机Ⅱ期研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Haakensen, V. D.; Ojlert, A. K.; Kefi, W.; Thunold, S. M. H.; Farooqi, S. J.; Nowak, A. K.; Chin, W. L.; Grundberg, O.; Szejniuk, W. M.; Cedres Perez, S. M.; Sorensen, J. B.; Dalen, T. S.; Lund-Iversen, M.; Bjaanaes, M. M.; Inderberg, E. M.; Helland, A.
Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/-UV1 telomerase vaccine
European Journal of Nuclear Medicine and Molecular Imaging
IF7.6
2024-08-120
OAAI
Thunold, Solfrid; Hernes, Eivor; Farooqi, Saima; Oejlert, asa Kristina; Francis, Roslyn J.; Nowak, Anna K.; Szejniuk, Weronika Maria; Nielsen, Soren Steen; Cedres, Susana; Perdigo, Marc Simo; Sorensen, Jens Benn; Meltzer, Carin; Mikalsen, Lars Tore Gyland; Helland, Aslaug; Malinen, Eirik; Haakensen, Vilde Drageset
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

不可切除的III期NSCLC患者放化疗后durvalumab的真实世界结局: PACIFIC-R的总生存期中期分析

ESMO OPEN
IF8.3
2024-06-017
OAAI
Filippi, A. R.; Bar, J.; Chouaid, C.; Christoph, D. C.; Field, J. K.; Fietkau, R.; Garassino, M. C.; Garrido, P.; Haakensen, V. D.; Kao, S.; Markman, B.; Mcdonald, F.; Mornex, F.; Moskovitz, M.; Peters, S.; Sibille, A.; Siva, S.; Heuvel, M. van den; Vercauter, P.; Anand, S.; Chander, P.; Licour, M.; Lima, A. R. de; Qiao, Y.; Girard, N.
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms

非小细胞肺癌的蛋白质组学揭示与特异性治疗靶点和免疫逃避机制相关的分子亚型

NATURE CANCER
IF28.5
2021-11-2254
OAAI
Lehtio, Janne; Arslan, Taner; Siavelis, Ioannis; Pan, Yanbo; Socciarelli, Fabio; Berkovska, Olena; Umer, Husen M.; Mermelekas, Georgios; Pirmoradian, Mohammad; Jonsson, Mats; Brunnstrom, Hans; Brustugun, Odd Terje; Purohit, Krishna Pinganksha; Cunningham, Richard; Asl, Hassan Foroughi; Isaksson, Sofi; Arbajian, Elsa; Aine, Mattias; Karlsson, Anna; Kotevskaz, Marija; Hansen, Carsten Gram; Haakensen, Vilde Drageset; Helland, Aslaug; Tamborero, David; Johansson, Henrik J.; Branca, Rui M.; Planckz, Maria; Staaf, Johan; Orre, Lukas M.
PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Pacific-r真实世界研究: 放化疗后接受durvalumab治疗的不可切除的III期NSCLC患者的治疗持续时间和无进展生存期的中期分析

ANNALS OF ONCOLOGY
IF65.4
2021-09-0114
OAAI
Girard, N.; Smit, H. J. M.; Sibille, A.; McDonald, F.; Mornex, F.; Garassino, M. C. C.; Filippi, A. R.; Peters, S.; Field, J. K.; Christoph, D. C.; Fietkau, R.; Haakensen, V. D.; Bar, J.; Chouaid, C.; Bray, V.; Kao, S.; Sawyer, W.; Allen, A.; Licour, M.; Garrido, P.

研究方向

暂未获取到该数据
Å
Åslaug Helland
H 指数:55论文数:527被引数:1.2万
M
Maria Moksnes Bjaanæs
H 指数:13论文数:58被引数:687
Å
Åsa Kristina Öjlert
H 指数:7论文数:36被引数:185
S
S.J. Farooqi
H 指数:5论文数:28被引数:79
A
Anne‐Lise Børresen‐Dale
H 指数:105论文数:595被引数:7.7万
H
Henrik Horndalsveen
H 指数:3论文数:19被引数:55
V
Vessela N. Kristensen
H 指数:61论文数:392被引数:2.0万
O
Ole Christian Lingjærde
H 指数:64论文数:479被引数:2.8万
T
Torben Lüders
H 指数:20论文数:85被引数:1,768
I
Irina Gromova
H 指数:43论文数:124被引数:5,464